Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03833427 |
| Title | Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme Corp. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| City of Hope National Medical Center ( Site 0004) | Duarte | California | 91010 | United States | Details | |
| START Midwest ( Site 0001) | Grand Rapids | Michigan | 49546 | United States | Details | |
| John Theurer Cancer Center ( Site 0002) | Hackensack | New Jersey | 07601 | United States | Details | |
| South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0003) | San Antonio | Texas | 78229 | United States | Details | |
| Princess Margaret Cancer Centre ( Site 0014) | Toronto | Ontario | M5G 1Z5 | Canada | Details | |
| CHU de Quebec Universite de Laval ( Site 0013) | Quebec | G1R 2J6 | Canada | Details |